![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 43, 30527-30533, October 22, 1999
From the Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
| |
ABSTRACT |
|---|
|
|
|---|
Human PICD was identified by homology
probing the data base of expressed sequence tags with the protein
sequence of Saccharomyces cerevisiae Idp3p, a peroxisomal
NADP+-dependent isocitrate dehydrogenase. The
human PICD cDNA contains a 1242-base pair open reading
frame, and its deduced protein sequence is 59% identical to yeast
Idp3p. Expression of PICD partially rescued the fatty acid
growth defect of the yeast idp3 deletion mutant suggesting
that PICD is functionally homologous to Idp3p. Kinetic studies on
bacterially expressed PICD demonstrated that this enzyme catalyzed the
oxidative decarboxylation of isocitrate to 2-oxoglutarate with a
specific activity of 22.5 units/mg and that PICD displayed
KM values of 76 µM for isocitrate and
112 µM for NADP+. In subcellular
fractionation experiments, we found PICD in both peroxisomes and
cytoplasm of human and rat liver cells, with approximately 27% of
total PICD protein associated with peroxisomes. The presence of PICD in
mammalian peroxisomes suggests roles in the regeneration of NADPH for
intraperoxisomal reductions, such as the conversion of 2,4-dienoyl-CoAs
to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume
2-oxoglutarate, namely the Isocitrate dehydrogenases catalyze the
nucleotide-dependent oxidative decarboxylation of isocitric
acid to 2-oxoglutarate. Mechanistically, these enzymes exist in two
distinct subclasses that utilize either NAD+ or
NADP+, respectively, as an electron acceptor. In mammalian
cells three highly similar isoforms of
NAD+-dependent isocitrate dehydrogenase have
been thoroughly examined and are localized to the mitochondrial matrix
(2) where they catalyze the allosterically regulated rate-limiting step
of the tricarboxylic acid cycle (3). Prior studies have also reported the existence of at least two NADP+-dependent
isocitrate dehydrogenases in mammalian cells, one of which is
mitochondrial whereas the other is cytosolic (4). Although the precise
metabolic roles of the NADP+-utilizing enzymes are not yet
clear, they are probably related to the production of NADPH for
biosynthetic processes in the cytoplasm and other cellular compartments
(5, 6).
It has long been suggested that peroxisomes may contain an
NADP+-dependent isocitrate dehydrogenase (7),
but molecular evidence to support this hypothesis has been provided
only recently. Two reports have established that the
Saccharomyces cerevisiae gene IDP3 encodes a
peroxisomal NADP+-dependent isocitrate
dehydrogenase (8, 9). Furthermore, the phenotypes of the
idp3 In this report we present the identification of PICD, a
human homolog of S. cerevisiae IDP3. Activity analysis and
kinetic characterization of a bacterially expressed form of PICD
revealed that this protein is an
NADP+-dependent isocitrate dehydrogenase, and
subcellular fractionation experiments demonstrated that PICD is
localized to both peroxisomes and the cytoplasm in both human and rat
cells. We discuss the potential metabolic roles of both peroxisomal and
cytoplasmic PICD.
Plasmids--
The human cDNA clone (GenBankTM
accession number AA313574) for the candidate peroxisomal
NADP+-dependent isocitrate dehydrogenase was
obtained from American Type Culture Collection (Manassas, VA) and was
sequenced in its entirety. Two forms of the PICD open
reading frame (ORF)1 were
amplified by PCR using the cDNA clone as a template. The complete
ORF was amplified using the primers
5'-AAAGTCGACAATGTCCAAAAAAATCAGTGGCGGT-3' and
5'-AAAGCGGCCGCTTAAAGTTTGGCCTGAGCTAGTTTG-3'. A form of
PICD lacking the final three codons of the ORF
(PICD Strains, Media, and Growth Curves--
All bacterial
manipulations were performed with the Escherichia coli
strain DH10B (21). The yeast strains BY4733 (22), BY4733,
idp3 Production of Recombinant PICD--
The plasmids pMBP-PICD and
pMBP-PICD
The vector pT7-PICD was used as a template for all in vitro
translations of PICD from a T7-coupled rabbit reticulocyte lysate system (TnT, Promega; Madison, WI). Reactions were carried out at
37 °C according to the manufacturer's suggestions.
Generation of Antibodies and Immunoblotting--
Bacterially
expressed MBP-PICD Analytical Procedures--
Isocitrate dehydrogenase activity was
monitored spectrophotometrically at 340 nm as described by Loftus
et al. (26), with the exception that assays were performed
at 20 °C. One unit of NADP+-dependent
isocitrate dehydrogenase activity is defined as the amount of enzyme
catalyzing the oxidative decarboxylation of 1.0 µmol of
D-isocitrate to 2-oxoglutarate in 1 min under standard assay conditions (26). A molar extinction coefficient
( Subcellular Fractionation--
Preparation of a post-nuclear
supernatant from HepG2 cells and fractionation of this post-nuclear
supernatant by ultracentrifugation on a 15-40% (w/v) linear Nycodenz
density gradient has been described (32). Following
ultracentrifugation, fractions (750 µl) were drawn from the bottom of
the gradient and assayed for a peroxisomal marker enzyme catalase, for
a mitochondrial marker enzyme succinate dehydrogenase, and for an
endoplasmic reticulum marker enzyme NADPH-cytochrome c
reductase. The proteins present in each fraction were then precipitated
by adding trichloroacetic acid to 15% and incubating on ice for 10 min, and the precipitate was collected by centrifugation at 15,000 × g for 5 min. The precipitated samples were prepared for
SDS-polyacrylamide gel electrophoresis as described by Dodt et
al. (32). Generation and fractionation of a post-nuclear supernatant from rat liver was performed as described (33), using a
15-42% (w/v) linear Nycodenz density gradient.
Selective Permeabilization Experiments--
Human hepatocellular
carcinoma cells (HepG2) were grown to confluency on two 10-cm dishes.
These cells were harvested with trypsin and washed with an isotonic
sucrose buffer as described previously (32). The washed cells were
divided into 6 aliquots, pelleted by centrifugation at 1,500 × g for 5 min, and placed on ice. The cells in individual
aliquots were gently resuspended in isotonic sucrose buffer containing
0, 50, 100, 250, and 500 µg/ml digitonin, and the remaining aliquot
was resuspended in the same buffer containing 500 µg/ml digitonin
with 1% Triton X-100. The cell suspensions were incubated on ice for
10 min and then centrifuged at 15,000 × g to yield a
pellet and supernatant. The soluble proteins present in the supernatant
were precipitated by adding trichloroacetic acid as described above,
and the samples were prepared for SDS-polyacrylamide gel
electrophoresis and immunoblotting as described (32).
Identification of a Human Homolog of S. cerevisiae
Idp3p--
IDP3 encodes the peroxisomal
NADP+-dependent isocitrate dehydrogenase of
S. cerevisiae (8, 9). We used the BLAST algorithm to scan
the human data base of expressed sequence tags (dbEST) for candidate
human homologs of yeast Idp3p. Successive rounds of prioritized BLAST
screening identified a human colon carcinoma cDNA (clone AA313574)
whose insert had the potential of encoding a protein with a high degree
of similarity to the N-terminal sequence of Idp3p. This cDNA was
sequenced in its entirety and was found to contain a 1242-base pair ORF
(Fig. 1). The initial ATG codon of this
ORF has a near-consensus match for high efficiency translation initiation (34, 35) and is preceded by three in-frame stop codons in
the 5'-untranslated region at positions
Idp3p plays a critical role in regenerating the NADPH equivalents
necessary to complete the PICD Encodes an NADP+-dependent Isocitrate
Dehydrogenase--
The fact that PICD expression was able
to complement the oleate growth defect of the idp3 The PICD Protein Is Bimodally Distributed between Peroxisomes and
the Cytosol--
The above data demonstrated that the human
PICD gene encodes a protein highly similar to S. cerevisiae Idp3p that can partially complement the yeast
idp3
We next tested whether PICD from any other mammals shared a similar
bimodal distribution. The anti-PICD antibodies detected a protein of
the appropriate molecular mass in rat liver homogenates (data not
shown), and we found that rat PICD was also present in both peroxisomes
and the cytoplasm (Fig. 5, A
and B). Comparative densitometry of the anti-PICD
immunoreactivity in peroxisome-containing fractions (numbers 1-8) with
the non-peroxisomal fractions (numbers 9-16) revealed that
approximately 27% of total cellular PICD was peroxisome-associated. We
compared this ratio to that of a cytoplasmic marker enzyme activity,
lactate dehydrogenase (Fig. 5C), to determine if the
peroxisome-associated PICD was due to contamination of the
peroxisome-containing fractions with cytoplasmic proteins. The very low
level of lactate dehydrogenase activity in the peroxisomal fractions
(2% total) confirmed that the peroxisomal PICD was not due to
cytoplasmic contamination and instead supported the hypothesis that
PICD is a bimodally distributed protein.
Although the simplest explanation for these data is that PICD is only
poorly imported into peroxisomes and that most PICD is cytoplasmic,
some studies have described peroxisomal proteins that are
preferentially lost from the organelle during homogenization and/or
fractionation (40). Therefore, in an alternative approach to determine
whether PICD is truly predominantly cytoplasmic, we permeabilized HepG2
cells with increasing amounts of digitonin and followed the amount of
PICD released as compared with the release of a peroxisomal marker
protein catalase (41). At low concentrations of digitonin, most PICD
was released from the cells, as expected for a predominantly
cytoplasmic protein (Fig. 6). In
contrast, release of catalase was observed only when all cellular membranes were permeabilized with 1% Triton X-100. Thus, the
cytoplasmic localization of PICD suggested by the subcellular
fractionation experiments appeared to reflect bona fide
cytoplasmic enzyme instead of peroxisomal PICD that had been released
by damage to the organelle.
Recent genetic and biochemical studies revealed the presence of an
NADPH-dependent isocitrate dehydrogenase, Idp3p, in
peroxisomes of S. cerevisiae. These studies also established
that Idp3p is essential for the activity of peroxisomal 2,4-dienoyl-CoA
reductase, an NADPH-dependent enzyme, and thus that Idp3p
is required for producing intraperoxisomal NADPH. To determine whether
mammalian peroxisomes also require intraperoxisomal enzymes for the
regeneration of enzyme cofactors, we searched for human homologs of
yeast IDP3, and we identified a single candidate gene,
PICD. We observed that human PICD can rescue the
phenotypes of the yeast idp3 Mammalian peroxisomes contain multiple NADPH-dependent
enzymes, including 2,4-dienoyl-CoA reductase (10, 11),
hydroxymethylglutaryl-CoA reductase (12-15), and acyl-CoA reductase
(42). Furthermore, they contain at least one enzyme, phytanoyl-CoA
In addition to resolving the intraperoxisomal source of NADPH and
2-oxoglutarate, the detection of PICD in human peroxisomes has
significant implications for peroxisome permeability. Prior studies of
mammalian peroxisomes have suggested that they contain a porin-like
protein and are permeable to virtually all small molecules, including
sugars as large as sucrose (44). This model implies that the substrates
and products of peroxisomal enzymatic reactions can diffuse freely
across the peroxisome membrane and, furthermore, that there is no need
for peroxisomal metabolite transporters and antiporters, such as those
present in the inner mitochondrial membrane. However, this model is
based primarily on in vitro data using purified peroxisomes
that are subject to the caveat that the organelle membranes may have
been damaged during purification. Interestingly, recent studies from
yeast (including the analysis of Idp3p) provide strong evidence that the membrane of yeast peroxisomes is impermeable to small metabolites such as NADP+, NAD+, CoA, acetyl-CoA, etc.
(45). Since a peroxisome with a freely permeable membrane should not
require an intraperoxisomal NADPH-regenerating enzymatic activity
a priori, the mere identification of PICD supports the
hypothesis that mammalian peroxisomes also have an impermeable membrane. This hypothesis predicts the existence of multiple
transporters to mediate the exchange of metabolites between the
peroxisome and cytoplasm. Consistent with this idea, mammalian
peroxisomes have been shown to contain at least four members of the
ATP-binding cassette family of transmembrane transporters (46-49) and
two members of the solute carrier family of antiporters (50).
In addition to being a component of peroxisomes, PICD is also located
in the cytoplasm of human cells. In fact, the amount of PICD in the
cytoplasm appears to be at least 3-fold greater than the amount that is
present in the peroxisome. Although the presence of a cytoplasmic
NADP+-dependent isocitrate dehydrogenase was
established previously (51), it was not known that a common gene
encoded both cytoplasmic and peroxisomal enzyme activities. We have
examined the mRNA products of PICD in mammalian cells,
and we find no evidence of alternative structures, indicating that a
single PICD polypeptide is differentially localized to both the
cytoplasm and peroxisome. PICD contains what would appear to be an
efficient PTS-1 (the protein terminates in the amino acids
Ala-Lys-Leu-COOH), and we have no evidence for why only a subset of
PICD is transported into peroxisomes. One possible explanation is that
the PICD C terminus may be masked by oligomerization or by interaction
with one or more cytoplasmic proteins, thereby preventing the
recognition of its PTS-1 by PEX5, the cytoplasmic PTS-1 receptor (32,
52, 53).
Although the molecular events involved in retaining PICD in the
cytoplasm remain to be elucidated, there is little doubt that PICD is
predominantly cytoplasmic. As for the function of cytoplasmic PICD,
this protein is likely to particpate in the production of NADPH for
cytoplasmic reductive chemical reactions (51). In mammalian liver
cytosol, the major NADPH-dependent reductive processes are
fatty acid synthesis and cholesterol synthesis. Whereas a large body of
work has established that the hexose monophosphate shunt serves as a
major source of the NADPH consumed by these processes, the role of
cytoplasmic PICD cannot be dismissed as insignificant. In fact, genetic
deficiencies in the enzyme glucose-6-phosphate dehydrogenase, which
catalyzes the first NADPH-yielding reaction of the hexose monophosphate
shunt, are well described and are among the most common enzymatic
defects known in humans (1). Clinically, such patients suffer from
acute hemolysis but do not present with deficiencies in either fatty
acid or sterol synthesis (1). That this enzymatic reaction, and thus
all NADPH-yielding steps of the hexose monophosphate shunt, can be
blocked without significant effects on fatty acid and sterol metabolism
(1) suggests that cytoplasmic PICD plays an important role in the generation of cytoplasmic NADPH.
-hydroxylation of phytanic acid. As for
cytoplasmic PICD, the phenotypes of patients with glucose-6-phosphate
dehydrogenase deficiency (Luzzatto, L., and Mehta, A. (1995) in
The Metabolic and Molecular Bases of Inherited Disease
(Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds) Vol. 3, 7th Ed., pp. 3367-3398, McGraw-Hill Inc., New York)
suggest that PICD serves a significant role in cytoplasmic NADPH
production, particularly under conditions that do not favor the use of
the hexose monophosphate shunt (Luzzatto et al.).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
mutant suggest that this enzyme is required to
regenerate the NADPH consumed by reductive processes inside the
peroxisome (8, 9). Mammalian peroxisomes also contain NADPH-consuming
enzymes such as 2,4-dienoyl-CoA reductase (10, 11) and
hydroxymethylglutaryl-CoA reductase (12-15) and may also require an
intraperoxisomal NADP+-dependent isocitrate
dehydrogenase. Moreover, such an enzyme has the potential to contribute
intraperoxisomal 2-oxoglutarate that is required by peroxisomal enzymes
such as phytanoyl-CoA
-hydroxylase (16-18).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
AKL) was amplified using the primer
5'-AAAGCGGCCGCTTACTGAGCTAGTTTGATCTTC-3' in
conjunction with the first primer above. Both sets of oligonucleotides
append SalI and NotI sites (underlined sequences)
at the 5'- and 3'-ends of the PICD ORF. All PCR reactions
were performed with a low error rate mixture of polymerases (Expand,
Roche Molecular Biochemicals). The PCR product from each reaction was
digested with SalI and NotI and cloned between
the SalI and NotI sites of pMBP (19). The
sequence of each form of the PICD ORF in pMBP was confirmed by automated fluorescent sequencing, and the resulting plasmids were
denoted pMBP-PICD and pMBP-PICD
AKL. The
SalI-NotI fragment of pMBP-PICD was excised and
transferred to the oleic acid-inducible yeast expression vector pOIE
(19), as well as the T7-based expression vector, pT7 (20).
::HIS3 (23), and BY4733,
pex8
::HIS3 (23) have been described.
Methods for yeast transformations, routine culture of yeast strains,
and growth curves have been described (19).
AKL are designed to express the PICD and PICD
AKL
proteins, respectively, in fusion with E. coli
maltose-binding protein (MBP). Induction of protein expression, cell
growth and lysis, and amylose-affinity chromatography methods were as
described in Geisbrecht et al. (19). Following elution of
the MBP-PICD fusion protein, the fractions containing highly purified
MBP-PICD (>95% pure by SDS-polyacrylamide gel electrophoresis) were
pooled, precipitated with 0.4 g/ml
(NH4)2SO4, aliquoted, and stored at
70 °C until use. Recombinant MBP-PICD
AKL and MBP were expressed
and purified according to a similar procedure.
AKL was used to elicit the production of
polyclonal anti-PICD antibodies in New Zealand White rabbits. Rabbits
were purchased from, maintained at, and immunized according to the
standard protocols of Cocalico Biologicals, Inc. (Reamstown, PA). Crude
serum was obtained from the supplier. The specificity of the crude sera
for PICD was confirmed as follows. Samples containing either total
human skin fibroblast protein (40 µg per lane, prepared as described
(24)), in vitro synthesized PICD, or rabbit reticulocyte
lysate alone were separated by SDS-polyacrylamide gel electrophoresis
and transferred to membranes. Immune sera were used at a 1:2500
dilution, and immunoblotting was performed as described in Crane
et al. (25). Following chemiluminescent detection (data not
shown), anti-PICD immunoreactivity was present as one band of
approximately 46 kDa in lanes corresponding to the fibroblast cellular
protein and in vitro synthesized PICD but not in the control
lane. Thus, the immune sera was judged to be specific for PICD.
340) of 6220 M
1
cm
1 was assumed for NADPH, and this figure was used in
the calculation of all reaction rates. Assays for catalase (a
peroxisomal marker) (27, 28), succinate dehydrogenase (a mitochondrial
marker) (29), NADPH-cytochrome c reductase (an endoplasmic
reticulum marker) (30), and lactate dehydrogenase (a cytosolic marker) (31) have been described. Total protein concentration was determined using the Bradford method (Bio-Rad) with bovine serum albumin as a
reference. Curve fitting was performed with GraFit data analysis software. Quantitation of film exposure was performed by densitometry using MacBas software (version 2.0).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
38,
41, and
135 relative
to the A of the putative initiator codon. The deduced product of this
cDNA is 59% identical to Idp3p (Fig.
2). Idp3p and PICD were more similar to
one another than to any other proteins in these species, indicating
that this cDNA (PICD) encoded the human homolog of yeast
Idp3p.

View larger version (64K):
[in a new window]
Fig. 1.
Structure of the human PICD cDNA and its deduced product. The nucleotide sequence of
the PICD cDNA is presented, together with the amino acid sequence
of its deduced protein product. Positions are shown to the
right, and the nucleotide sequence is numbered from the
first nucleotide of the PICD ORF. The deduced protein is
predicted to terminate in the PTS-1 Ala-Lys-Leu-COOH
(underlined). Three in-frame, upstream stop codons in the
5'-untranslated region are also underlined.

View larger version (52K):
[in a new window]
Fig. 2.
Human PICD is related to yeast IDP3. The
deduced products of the human PICD and yeast IDP3
genes were aligned using the Clustal algorithm and DNASTAR software.
Identical residues are boxed in black and shown
in reverse type.
-oxidation of unsaturated fatty acids (8,
9). Oleic acid (C18:
9) is such a fatty acid, and yeast strains
lacking the IDP3 gene (idp3
) display a reduced growth rate on oleic acid (9). In order to test whether or not the
PICD cDNA encoded a functional homolog of Idp3p, we
examined the ability of PICD expression to complement the
oleate growth defect of an idp3
yeast strain (BY4733,
idp3
::HIS3) (23). Growth rates were
determined in oleic acid medium for the wild-type strain BY4733 (22),
the idp3
derivative of BY4733 containing the
PICD cDNA on an episomal plasmid, the idp3
derivative of BY4733, and the pex8
derivative of BY4733
(BY4733, pex8
::HIS3) (pex
mutants of S. cerevisiae are unable to grow on fatty acids (36)). We observed that expression of PICD restored growth
of the idp3
strain to approximately 75% of wild-type or
about twice the growth observed for the idp3
strain alone
(Fig. 3).

View larger version (19K):
[in a new window]
Fig. 3.
Expression of human PICD in
an idp3
strain of S. cerevisiae restores growth on oleic acid. Growth of
idp3
cells expressing PICD from an episomal
plasmid (filled circle) was monitored and compared with that
of idp3
(open circle), wild-type (filled
square), and pex8
cells (open square)
over a period of 150 h. Expression of PICD was observed
to complement the growth defect of idp3
cells, suggesting
that PICD is a functional homolog of Idp3.
strain
suggested that the PICD protein, like Idp3, was an
NADP+-dependent isocitrate dehydrogenase. To
test this directly, we expressed a recombinant form of PICD in fusion
with E. coli maltose-binding protein (MBP), purified this
protein by amylose affinity chromatography, and assayed the purified
protein for NADP+-dependent isocitrate
dehydrogenase activity. The purified MBP-PICD protein catalyzed the
oxidative decarboxylation of isocitric acid with a specific activity of
22.5 ± 2.3 units/mg PICD, whereas purified MBP alone was devoid
of detectable isocitrate dehydrogenase activity (Table
I). In addition, we were unable to detect
isocitrate dehydrogenase activity with purified MBP-PICD when
NADP+ was replaced with NAD+ (Table I). To
examine the kinetics of the PICD catalyzed reaction in more detail, we
measured the initial velocities of the enzymatic reaction at various
isocitrate and NADP+ concentrations and used nonlinear
least squares analysis to determine both KM
constants of the enzyme (data not shown). The KM
constants for the purified enzyme were found to be 76 µM
for isocitrate and 112 µM for NADP+. These
values are in the range of those reported for a bacterially expressed
form of Idp3p (9). Interestingly for PICD, the KM constant observed with respect to NADP+ is higher than for
isocitrate, a unique property that has not been observed for the
peroxisomal NADP+-dependent isocitrate
dehydrogenases of yeasts (9, 37).
Isocitrate dehydrogenase activities of bacterially expressed PICD
(units/mg)
mutant and that PICD has
NADP+-dependent isocitrate dehydrogenase
activity. The presence of the type 1 peroxisomal targeting signal
sequence (PTS-1), Ala-Lys-Leu-COOH, at the C terminus of PICD suggested
that this enzyme might be targeted to peroxisomes in human cells (38).
Rabbit polyclonal antibodies were generated against a recombinant form
of PICD lacking its last three amino acids (to avoid generating
antibodies to the PTS-1 (39)) and were used to examine PICD
distribution in subcellular fractionation experiments. Human
hepatocellular carcinoma (HepG2) cells were homogenized, and a
post-nuclear supernatant was prepared by differential centrifugation.
This post-nuclear supernatant was fractionated further by
ultracentrifugation on a linear, 15-40% Nycodenz density gradient.
Equal portions of each fraction were assayed for peroxisomal,
mitochondrial, and endoplasmic reticulum marker enzyme activities (Fig.
4A) and for PICD by Western
blot (Fig. 4B). PICD immunoreactivity (approximate mass 46 kDa) was found to be bimodally distributed across the gradient.
Significant amounts of PICD were found to colocalize with the
peroxisomal marker enzyme catalase, suggesting that PICD is a resident
peroxisomal enzyme. However, we observed that the majority of PICD was
present in cytosolic fractions at the top of the gradient. Based on the
amount of catalase present at the top of the gradient, the levels of
PICD in these fractions were disproportionate to the amount expected
from peroxisome rupture during homogenization and centrifugation. Thus
PICD appeared to be present in the cytoplasm as well as peroxisomes.

View larger version (23K):
[in a new window]
Fig. 4.
Endogenous PICD is present in the peroxisomes
and cytosol of HepG2 cells. A post-nuclear supernatant from human
hepatocellular carcinoma cells (HepG2) was fractionated by Nycodenz
density gradient ultracentrifugation. A, equal portions of
each fraction were assayed for a peroxisomal marker enzyme, catalase
(black bar), a mitochondrial marker enzyme, succinate
dehydrogenase (gray bar), and for an endoplasmic reticulum
marker enzyme, NADPH-cytochrome c reductase (open
bar). B, equal portions of each fraction were also
separated by SDS-polyacrylamide gel electrophoresis, transferred to
membranes, and blotted with anti-PICD antibodies.

View larger version (21K):
[in a new window]
Fig. 5.
Rat liver PICD is bimodally distributed to
the peroxisome and cytoplasm. A post-nuclear supernatant of rat
liver was fractionated by Nycodenz density gradient
ultracentrifugation. A, equal portions of each fraction were
assayed for a peroxisomal marker enzyme, catalase (black
bar), and a mitochondrial marker enzyme, succinate dehydrogenase
(gray bar). B, equal portions of each fraction
were also separated by SDS-polyacrylamide gel electrophoresis,
transferred to membranes, and blotted with anti-PICD antibodies.
C, fractions were also assayed for a cytosolic marker
enzyme, lactate dehydrogenase (black bar), to control for
cytoplasmic contamination in higher density fractions.

View larger version (22K):
[in a new window]
Fig. 6.
Detection of cytoplasmic PICD by differential
permeabilization. Human HepG2 cells were incubated with increasing
concentrations of digitonin as shown (0, 50, 100, 250, 500, and 500 µg/ml + 1% Triton X-100) and then separated into a supernatant and
pellet by differential centrifugation. Proteins present in the
individual supernatants were precipitated by trichloroacetic acid,
separated by SDS-polyacrylamide gel electrophoresis, and transferred to
membranes. The PICD present in each sample was detected by immunoblot,
as was the peroxisomal matrix protein, catalase. The extraction of PICD
following treatment with limiting amounts of digitonin confirmed that
PICD is found in the cytosol of intact mammalian cells.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
mutant and that
PICD encodes a peroxisomal protein with intrinsic
NADP+-dependent isocitrate dehydrogenase
activity, thereby providing strong evidence that PICD is the
human homolog of yeast IDP3.
-hydroxylase, that requires 2-oxoglutarate as a cosubstrate
(16-18). However, the source of the intraperoxisomal NADPH and
2-oxoglutarate that are required by these enzymes has not previously
been identified. The presence of PICD in human peroxisomes suggests
that this enzyme is responsible for generating these compounds within
the organelle. Furthermore, it suggests that mutations in PICD may
result in defects in multiple peroxisomal metabolic pathways, namely
the oxidation of unsaturated fatty acids and the degradation of
phytanic acid. This combination of phenotypes is highly likely to
result in human disease given that defects in phytanic acid degradation alone are sufficient to cause Refsum disease (18, 43). Yet to be
determined is the source of intraperoxisomal isocitrate, the PICD
substrate, as well as the mechanism(s) by which peroxisomes take up the
biochemical quantities of NADP+ and/or NADPH required to
initiate a metabolically relevant NADP+/NADPH cycle
within the organelle.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Stephanie Mihalik and Paul Watkins for their generous assistance with the subcellular fractionation and selective permeabilization experiments.
| |
FOOTNOTES |
|---|
* This work was supported by Grant DK45787 from the National Institutes of Health (to S. J. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF113917.
To whom correspondence should be addressed: Dept. of Biological
Chemistry, The Johns Hopkins University School of Medicine, 725 N. Wolfe St., Baltimore, MD 21205. Tel.: 410-955-3085; Fax: 410-955-0215.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: ORF, open reading frame; PCR, polymerase chain reaction; MBP, maltose-binding protein.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Luzzatto, L., and Mehta, A. (1995) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R. , Beaudet, A. L. , Sly, W. S. , and Valle, D., eds), 7th Ed., Vol. 3 , pp. 3367-3398, McGraw-Hill Inc., New York |
| 2. |
Ramachandran, N.,
and Colman, R. F.
(1980)
J. Biol. Chem.
255,
8859-8864 |
| 3. | Plaut, G. W. E. (1970) Curr. Top. Cell. Regul. 2, 1-27 |
| 4. | Plaut, G. W., Cook, M., and Aogaichi, T. (1983) Biochim. Biophys. Acta 760, 300-308[Medline] [Order article via Infotrieve] |
| 5. | Flint, A. P. F., and Denton, R. M. (1970) Biochem. J. 117, 73-83[Medline] [Order article via Infotrieve] |
| 6. | Klinken, S. P., and Stevenson, P. M. (1977) Eur. J. Biochem. 81, 327-332[Medline] [Order article via Infotrieve] |
| 7. |
Leighton, F.,
Poole, B.,
Beaufay, H.,
Baudhuin, P.,
Coffey, J. W.,
Fowler, S.,
and DeDuve, C.
(1968)
J. Cell Biol.
37,
482-513 |
| 8. | van Roermund, C. W., Hettema, E. H., Kal, A. J., van den Berg, M., Tabak, H. F., and Wanders, R. J. (1998) EMBO J. 17, 677-687[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Henke, B.,
Girzalsky, W.,
Berteaux-Lecellier, V.,
and Erdmann, R.
(1998)
J. Biol. Chem.
273,
3702-3711 |
| 10. | Fransen, M., Van Veldhoven, P., and Subramani, S. (1999) Biochem. J. 340, 561-568 |
| 11. |
Geisbrecht, B.,
Liang, X.,
Morrell, J.,
Schulz, H.,
and Gould, S.
(1999)
J. Biol. Chem.
274,
25814-25820 |
| 12. |
Keller, G. A.,
Barton, M. C.,
Shapiro, D. J.,
and Singer, S. J.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
770-774 |
| 13. |
Keller, G.,
Pazirandeh, M.,
and Krisans, S.
(1986)
J. Cell Biol.
103,
875-886 |
| 14. | Rusnak, N., and Krisans, S. K. (1987) Biochem. Biophys. Res. Commun. 148, 890-895[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Krisans, S. K. (1996) Ann. N. Y. Acad. Sci. 804, 142-164[Abstract] |
| 16. | Mihalik, S. J., Rainville, A. M., and Watkins, P. A. (1995) Eur. J. Biochem. 232, 545-551[Medline] [Order article via Infotrieve] |
| 17. | Wanders, R. J., Jansen, G., van Roermund, C. W., Denis, S., Schutgens, R. B., and Jakobs, B. S. (1996) Ann. N. Y. Acad. Sci. 804, 450-460[Abstract] |
| 18. | Mihalik, S., Morrell, J., Kim, D., Sacksteder, K., Watkins, P., and Gould, S. (1997) Nat. Genet. 17, 185-189[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Geisbrecht, B. V.,
Zhu, D.,
Schulz, K.,
Nau, K.,
Morrell, J. C.,
Geraghty, M.,
Schulz, H.,
Erdmann, R.,
and Gould, S. J.
(1998)
J. Biol. Chem.
273,
33184-33191 |
| 20. |
Geisbrecht, B. V.,
Zhang, D.,
Schulz, H.,
and Gould, S. J.
(1999)
J. Biol. Chem.
274,
21797-21803 |
| 21. |
Grant, S. G.,
Jessee, J.,
Bloom, F. R.,
and Hanahan, D.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
4645-4649 |
| 22. | Baker-Brachmann, C., Davies, A., Cost, G. J., Caputo, E., Li, J., Hieter, P., and Boeke, J. D. (1998) Yeast 14, 115-132[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Geraghty, M. T.,
Bassett, D.,
Morrell, J. C.,
Gatto, G. J.,
Bai, J.,
Geisbrecht, B. V.,
Hieter, P.,
and Gould, S. J.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2937-2942 |
| 24. |
Dodt, G.,
and Gould, S. J.
(1996)
J. Cell Biol.
135,
1763-1774 |
| 25. |
Crane, D. I.,
Kalish, J. E.,
and Gould, S. J.
(1994)
J. Biol. Chem.
269,
21835-21844 |
| 26. | Loftus, T., Hall, L., Anderson, S., and McAlister-Henn, L. (1994) Biochemistry 33, 9661-9667[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Moreno de la Garza, M., Schultz-Borchardt, U., Crabb, J. W., and Kunau, W.-H. (1985) Eur. J. Biochem. 148, 285-291[Medline] [Order article via Infotrieve] |
| 28. | Peters, T. J., Muller, M., and de Duve, C. (1972) J. Exp. Med. 136, 1117-1139[Abstract] |
| 29. | Pennington, R. J. (1961) Biochem. J. 80, 649-654[Medline] [Order article via Infotrieve] |
| 30. |
Beaufay, H.,
Amar-Costesec, A.,
Feytmans, E.,
Thines-Sempoux, D.,
Wibo, M.,
Robbi, M.,
and Berthet, J.
(1974)
J. Cell Biol.
61,
188-200 |
| 31. | Storrie, B., and Madden, E. (1990) Methods Enzymol. 182, 203-225[Medline] [Order article via Infotrieve] |
| 32. | Dodt, G., Braverman, N., Wong, C., Moser, A., Moser, H. W., Watkins, P., Valle, D., and Gould, S. J. (1995) Nat. Genet. 9, 115-124[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Mihalik, S. J. (1992) Prog. Clin. Biol. Res. 357, 239-244 |
| 34. |
Kozak, M.
(1989)
J. Cell Biol.
108,
229-241 |
| 35. | Kozak, M. (1992) Annu. Rev. Cell Biol. 8, 197-225[CrossRef] |
| 36. |
Erdmann, R.,
Veenhuis, D.,
Mertens, D.,
and Kunau, W.-H.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
5419-5423 |
| 37. | Yamamoto, S., Atomi, H., Ueda, M., and Tanaka, A. (1995) Arch. Microbiol. 163, 104-111[Medline] [Order article via Infotrieve] |
| 38. |
Gould, S. J.,
Keller, G. A.,
Hosken, N.,
Wilkinson, J.,
and Subramani, S.
(1989)
J. Cell Biol.
108,
1657-1664 |
| 39. |
Gould, S. J.,
Krisans, S.,
Keller, G. A.,
and Subramani, S.
(1990)
J. Cell Biol.
110,
27-34 |
| 40. |
Krisans, S.,
Ericsson, J.,
Edwards, P.,
and Keller, G.
(1994)
J. Biol. Chem.
269,
14165-14169 |
| 41. |
Matsuzono, Y.,
Kinoshita, N.,
Tamura, S.,
Shimozawa, N.,
Hamasaki, M.,
Ghaedi, K.,
Wanders, R. J.,
Suzuki, Y.,
Kondo, N.,
and Fujiki, Y.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2116-2121 |
| 42. | Wanders, R. J., and Tager, J. M. (1998) Mol. Aspects Med. 19, 69-154[Medline] [Order article via Infotrieve] |
| 43. | Jansen, G. A., Ofman, R., Ferdiandusse, S., Ijlst, L., Muijsers, A. O., Skjeldal, O. H., Stokke, O., Jakobs, C., Besley, G. T. N., Wraith, J. E., and Wanders, R. J. A. (1997) Nat. Genet. 17, 190-193[CrossRef][Medline] [Order article via Infotrieve] |
| 44. |
Van Veldhoven, P. P.,
Just, W. W.,
and Mannaerts, G. P.
(1987)
J. Biol. Chem.
262,
4310-4318 |
| 45. | van Roermund, C. W., Elgersma, Y., Singh, N., Wanders, R. J., and Tabak, H. F. (1995) EMBO J. 14, 3480-3486[Medline] [Order article via Infotrieve] |
| 46. |
Kamijo, K.,
Taketani, S.,
Yokata, S.,
Osumi, T.,
and Hashimoto, T.
(1990)
J. Biol. Chem.
265,
4534-4540 |
| 47. |
Mosser, J.,
Lutz, Y.,
Stoeckel, M. E.,
Sarde, C. O.,
Kretz, C.,
Douar, A. M.,
Lopez, J.,
Aubourg, P.,
and Mandel, J. L.
(1994)
Hum. Mol. Genet.
3,
265-271 |
| 48. |
Shani, N.,
Jimenez-Sanchez, G.,
Steel, G.,
Dean, M.,
and Valle, D.
(1997)
Hum. Mol. Genet.
6,
1925-1931 |
| 49. |
Lombard-Platet, G.,
Savary, S.,
Sarde, C. O.,
Mandel, J. L.,
and Chimini, G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
1265-1269 |
| 50. | Wylin, T., Baes, M., Brees, C., Mannaerts, G. P., Fransen, M., and Van Veldhoven, P. P. (1999) Eur. J. Biochem. 258, 332-338[Medline] [Order article via Infotrieve] |
| 51. |
Jennings, G. T.,
Sechi, S.,
Stevenson, P. M.,
Tuckey, R. C.,
Parmelee, D.,
and McAlister-Henn, L.
(1994)
J. Biol. Chem.
269,
23128-23134 |
| 52. |
McCollum, D.,
Monosov, E.,
and Subramani, S.
(1993)
J. Cell Biol.
121,
761-774 |
| 53. |
van der Leij, I.,
Fransen, M. M.,
Elgersma, Y.,
Distel, B.,
and Tabak, H. F.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
11782-11786 |
This article has been cited by other articles:
![]() |
V. Contreras-Shannon, A.-P. Lin, M. T. McCammon, and L. McAlister-Henn Kinetic Properties and Metabolic Contributions of Yeast Mitochondrial and Cytosolic NADP+-specific Isocitrate Dehydrogenases J. Biol. Chem., February 11, 2005; 280(6): 4469 - 4475. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, J. Zhao, Z. Xu, B. Peng, Q. Huang, E. Arnold, and J. Ding Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity J. Biol. Chem., August 6, 2004; 279(32): 33946 - 33957. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shechter, P. Dai, L. Huo, and G. Guan IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells J. Lipid Res., November 1, 2003; 44(11): 2169 - 2180. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yoshihara, T. Hamamoto, R. Munakata, R. Tajiri, M. Ohsumi, and S. Yokota Localization of Cytosolic NADP-dependent Isocitrate Dehydrogenase in the Peroxisomes of Rat Liver Cells: Biochemical and Immunocytochemical Studies J. Histochem. Cytochem., September 1, 2001; 49(9): 1123 - 1132. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Szewczyk, A. Andrianopoulos, M. A. Davis, and M. J. Hynes A Single Gene Produces Mitochondrial, Cytoplasmic, and Peroxisomal NADP-dependent Isocitrate Dehydrogenase in Aspergillus nidulans J. Biol. Chem., September 28, 2001; 276(40): 37722 - 37729. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |